Extension Study for 2993-112

Completed · Phase 3

Conditions studied: Type 2 Diabetes Mellitus

In brief

This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing Protocol 2993-112 are eligible to enroll.

Key facts

Study ID
NCT01789957
Run by
AstraZeneca
People needed
225
Starts
2002-09-01
Expected to finish
2004-06-01
Last updated by the study team
2015-02-24

Who can join

Age: 16 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.